Close Menu

A news piece in this week's Science reports that ECell International (ESI), a Singapore-based company, is stopping research work on human embryonic stem cells due to increasing lack of investor interest. The time lag from lab to clinic is too long, investors say, but several companies, including Geron and ACT, are not giving up, claiming they have products in the pipeline.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.